Austria Works On Method To Improve Price Transparency
Understanding Public R&D Funding May Lead To Better Pricing Policies
Executive Summary
Austria’s health technology appraisal institute aims to further discussion on public investments in R&D and medicines pricing transparency.
You may also be interested in...
More Drug Price Disclosure In Store As WHO Delegates Pass Landmark Resolution
Many see the World Health Assembly resolution on drug pricing transparency as a game changer and welcome the fact that it will shine light on an area that critics says is far too opaque. Some are unhappy that the final version is not as strong as the original draft, but industry will be relieved the WHA ultimately did not adopt a requirement for mandatory disclosure of R&D costs.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.